Related Experiment Video
Updated: May 21, 2026

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
Published on: April 4, 2025
Antioxidants in kidney diseases: the impact of bardoxolone methyl
Jorge Rojas-Rivera1, Alberto Ortiz, Jesus Egido
1Laboratory of Renal and Vascular Pathology, Division of Nephrology and Hypertension, IIS Fundación Jiménez Díaz, Autonoma University of Madrid, 28040 Madrid, Spain.
Abstract:
Drugs targeting the renin-angiotensin-aldosterone system (RAAS) are the mainstay of therapy to retard the progression of proteinuric chronic kidney disease (CKD) such as diabetic nephropathy. However, diabetic nephropathy is still the first cause of end-stage renal disease. New drugs targeted to the pathogenesis and mechanisms of progression of these diseases beyond RAAS inhibition are needed. There is solid experimental evidence of a key role of oxidative stress and its interrelation with inflammation on renal damage. However, randomized and well-powered trials on these agents in CKD are scarce. We now review the biological bases of oxidative stress and its role in kidney diseases, with focus on diabetic nephropathy, as well as the role of the Keap1-Nrf2 pathway and recent clinical trials targeting this pathway with bardoxolone methyl.
Related Concept Videos
Renal Drug Excretion: Overview
A nephron consists of two primary structures: the renal corpuscle and the renal tubule. The renal corpuscle contains the glomerulus, a network of capillaries where the first step of renal excretion, glomerular filtration, occurs. Blood pressure forces water, ions, and small molecules out...
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Chronic Kidney Disease II: Clinical Manifestations
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
Chronic Kidney Disease III: Interprofessional Care
